Merck Halts Molnupiravir Trial in Hospitalized COVID-19 Patients; Outpatient Study to Continue
MOVe-OUT is a placebo-controlled, double-blind phase 2/3 study investigating the efficacy and safety of molnupiravir in non-hospitalized patients.
Respiratory Diseases/Disorders
Self-Administration Option Approved for Xolair Prefilled Syringe
Xolair, an anti-immunoglobulin E antibody, is indicated for the treatment of moderate to severe persistent asthma, chronic idiopathic urticaria, and nasal polyps.
Chest CT Indicates Mortality Risk in COPD
Individuals with higher SAT index had lower risks for mortality, while higher IMAT index linked to higher mortality risk
First US Trachea Transplant Patient Breathing Freely
So far, patient has not had any complications or signs of rejection
Cystic Fibrosis Treatments
The Pulmonary Clinical Practice Guidelines Committee of the Cystic Fibrosis (CF) Foundation provided updated recommendations on the use of available chronic treatments for Cystic Fibrosis based on current evidence.
Abbott’s COVID-19 Rapid Antigen Test Authorized for OTC Serial Asymptomatic Testing
The test has been authorized for home use to collect nasal swab samples from individuals 2 years of age and older.
Tyvaso Approved for Pulmonary Hypertension With Interstitial Lung Disease
The sNDA approval is supported by data from the phase 3 INCREASE study that evaluated Tyvaso inhalation solution in 326 adults with PH-ILD.
FDA: Abuse/Misuse of OTC Nasal Decongestant Can Lead to Major Health Complications
Since January 1, 2000, there have been 460 documented cases of propylhexedrine abuse or misuse reported to US poison control centers.
FDA Expands Use of Bioelectronic Device ClearUp to Include Sinus Congestion
The bioelectronic device was previously approved for treating sinus pain due to allergic rhinitis.
Results Announced in Phase 3 Trial of Ruxolitinib in COVID-19 Associated ARDS
Patients were randomized to receive either ruxolitinib 5mg twice daily (BID) plus standard of care (SoC), ruxolitinib 15mg BID plus SoC or placebo plus SoC.
